Mentari Therapeutics Goes Public Through $421M Reverse Merger to Advance Novel PACAP-Targeting Migraine Therapies
核心洞察
Mentari Therapeutics (搜索) plans to go public through a reverse merger with InMed Pharmaceuticals, creating a combined company valued at $421 million focused on antibody drugs for migraine prevention.
The deal includes a $290 million private placement led by Fairmount (搜索) and other major investors, providing funding through 2028 to support clinical development of two lead programs targeting the PACAP (搜索) protein.
Mentari's approach targets PACAP (搜索), a nervous system protein that regulates stress and triggers migraine symptoms, offering potential relief for patients inadequately controlled by current CGRP-blocking therapies.
Privately held Mentari Therapeutics (搜索) is set to enter the public markets through a reverse merger with InMed Pharmaceuticals, creating a combined entity valued at approximately $421 million that will focus on developing antibody drugs for migraine prevention. The transaction, announced Tuesday, represents a significant bet on a novel therapeutic approach targeting the PACAP (搜索) protein pathway.
The deal has received board approval from both companies and is expected to close in the second half of this year. Under the terms, InMed shareholders will retain roughly 1.5% ownership of the combined company, which will operate under the Mentari name and trade on Nasdaq under a new ticker symbol.
Major Funding Round Supports Clinical Development
Central to the transaction is a concurrent private placement that will generate gross proceeds of approximately $290 million. The funding round was led by Fairmount (搜索), a Pennsylvania-based investment firm, with participation from more than a dozen institutional investors including Blackstone Multi-Asset Investing, Wellington Management, a16z Bio + Health, and Perceptive Advisors.
This substantial capital infusion is designed to support the combined company's operations through 2028, by which time Mentari anticipates having clinical data for its two lead therapeutic programs. The funding timeline aligns with the company's clinical development milestones for its novel migraine prevention candidates.
Novel PACAP-Targeting Approach
Mentari's therapeutic programs emerged from Paragon Therapeutics (搜索), a biotech incubator that has spawned multiple companies developing treatments for cancer, immune disorders, and neurological diseases. The company is exploring migraine prevention through inhibition of PACAP (搜索) (Pituitary Adenylate Cyclase-Activating Polypeptide), a nervous system protein that regulates stress responses.
When triggered, PACAP (搜索) causes pain-sensing nerves to fire and blood vessels in the head to drastically widen, contributing to migraine pathophysiology. This mechanism represents a distinct approach from existing migraine therapies, potentially offering new treatment options for patients with inadequate responses to current medications.
Addressing Unmet Medical Need
The therapeutic rationale for Mentari's approach is underscored by significant gaps in current migraine treatment efficacy. According to statistics cited by InMed, close to half of patients on currently available treatments don't experience a 50% decrease in monthly migraine days, and fewer than one-third report a 75% reduction in migraine frequency.
This unmet need has created opportunities for companies targeting alternative pathways beyond the established CGRP (Calcitonin Gene-Related Peptide) mechanism. CGRP-blocking therapies, exemplified by Lundbeck's Vyepti (eptinezumab), received marketing approval in 2020 and represent the current standard for migraine prevention.
Clinical Development Pipeline
Mentari's development portfolio centers on two primary programs: MT-001 and MT-002. MT-001 is a monoclonal antibody that specifically targets PACAP (搜索) alone and is positioned to deliver Phase 2 proof-of-concept data by 2028. MT-002 represents a more sophisticated bispecific antibody approach designed to simultaneously target both PACAP and CGRP pathways.
The bispecific strategy could potentially offer enhanced efficacy by blocking multiple migraine-triggering mechanisms. Phase 1 data from MT-002 studies in healthy volunteers are expected by 2027, providing an earlier readout on the safety and pharmacological profile of this dual-targeting approach.
Competitive Landscape
Mentari enters a competitive field where PACAP (搜索) has attracted attention from other pharmaceutical companies. Slate Medicines (搜索), a startup co-founded by RA Capital Management, recently secured $130 million in funding to advance an experimental PACAP-targeting medicine in-licensed from China's DartsBio Pharmaceuticals (搜索).
Further along in development, Lundbeck has demonstrated clinical success with its PACAP (搜索)-targeting candidate acquired through the $2 billion acquisition of Alder BioPharmaceuticals (搜索). The Danish company announced earlier this year that this drug succeeded as a migraine prevention treatment in a second mid-stage study, with plans to discuss late-stage program design with regulators.
Leadership and Governance
The combined company will be governed by the existing Mentari board, with Julie Bruno, a growth partner at Fairmount (搜索), serving as chair. The board will include Michelle Pernice, an operating partner at Fairmount, and Laura Sandler, chief operating officer at Oruka Therapeutics, another Paragon company.
InMed CEO Eric Adams characterized the transaction as "an excellent opportunity for InMed shareholders to participate in the development of an exciting new drug pipeline with significant therapeutic and commercial potential." Adams noted that Mentari's lead programs "have tremendous potential to expand and reshape the migraine treatment and prevention market."
The reverse merger structure provides Mentari with immediate public market access while leveraging InMed's existing Nasdaq listing, though InMed's stock performance has been challenging, trading as a penny stock for most of this year after significant declines between mid-2021 and early 2023.